Generics' challenge was found to have been concentrated on patents for Boryung's hypertension complex "Dukarb," Novartis' heart failure treatment "Entresto," and Hanmi Pharmaceutical's asthma treatment "Monterizine. The number of companies targeting the patent alone amounts to 45 Dukarb companies, 24 Entresto companies, and 22 Monterizine companies.

◆Focus on requesting a trial on Dukarb, Entresto, and Monterizine patents

According to the pharmaceutical industry on the 22nd, referees have been filed for 20 patents for 9 drugs so far this year. A total of 68 companies have requested patent trials. Patent attacks were concentrated on Boryung's Dukarb. After Arlico filed a passive trial